federal_register: 2024-28210
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-28210 | Anesthetic and Analgesic Drug Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application 761393 for Condoliase Injection | Notice | The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document. | 2024-12-02 | 2024 | 12 | https://www.federalregister.gov/documents/2024/12/02/2024-28210/anesthetic-and-analgesic-drug-products-advisory-committee-notice-of-meeting-establishment-of-a | https://www.govinfo.gov/content/pkg/FR-2024-12-02/pdf/2024-28210.pdf | Health and Human Services Department; Food and Drug Administration | 221,199 | The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (the Committee). The general function of the Committee is to provide advice and... |